Agenus Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
38.6%projected annual EPS growth
Analyst Coverage
1analyst covering
FY Revenue (est.)
$184.7Mnext fiscal year
FY EPS (est.)
$0.50next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly35MTarget: Sufficient capital to fund critical expenses into 2027
Pre-commercial Product Revenue (BOT+BAL Early Access) Quarterly4.6MTarget: Continued expansion of paid named-patient programs globally
Annualized Ongoing Operating Expenses Annually50MTarget: Maintain operating expense base around $50 million framework
Watch Items
- Phase 3 BATTMAN Trial EnrollmentTrigger: First patient enrolled in April 2026; target enrollment of approximately 830 patientsAction: Monitor site activation across CCTG, GI Cancer Trials in Australia, and PRODIGE networks to ensure rapid enrollment.
- Going Concern Risk and Capital RaisingTrigger: Accumulated deficit of $2.14 billion as of March 31, 2026Action: Evaluate regional collaborations, partnering opportunities, and at-the-market equity programs to secure long-term funding.
- Regulatory Filings for BOT+BALTrigger: Planned U.S. Accelerated Approval and EU Conditional Approval filings in 2026Action: Track FDA and EMA interactions, particularly regarding the refractory MSS mCRC patient cohort without active liver metastases.
Research as of 19 Jun 2026